303810 — Dongkook Life Science Co Income Statement
0.000.00%
Last trade - 00:00- KR₩120bn
- KR₩151bn
- KR₩132bn
Annual income statement for Dongkook Life Science Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 102,668 | 107,234 | 120,161 | 131,816 |
| Cost of Revenue | ||||
| Gross Profit | 21,858 | 22,193 | 25,260 | 28,588 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Depreciation and Amortization | ||||
| Total Operating Expenses | 95,871 | 101,004 | 111,632 | 119,900 |
| Operating Profit | 6,797 | 6,230 | 8,530 | 11,916 |
| Gain / Loss on Sale of Assets | ||||
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | 6,433 | 5,281 | 4,830 | 4,753 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | 5,858 | 4,239 | 4,167 | 2,245 |
| Net Income Before Extraordinary Items | ||||
| Net Income | 5,858 | 4,239 | 4,167 | 2,245 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | 5,858 | 4,239 | 4,167 | 2,245 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | 183 | 133 | 110 | 70 |
| Dividends per Share |